Testosterone at higher doses can thicken blood slightly
TRANSCEND-T2D-1, the companion type 2 diabetes trial, was published simultaneously in The Lancet and showed A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs, while TRIUMPH-1 supplied the knee osteoarthritis and obstructive sleep apnea data
The organizations seeing the greatest success are focusing on balanced strategies that combine thoughtful coverage design, clinical support, utilization management, and ongoing evaluation of outcomes
[1] [2] Marketed under the brand names Mounjaro (for diabetes) and Zepbound (for weight loss), tirzepatide represents a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists
It differs from native IGF-1 by having an arginine substitution at the third amino acid (R3) and an additional 13 amino acids at the N-terminus, making it significantly more potent in receptor activation studies
Their value lies in comprehensive risk reduction